Nadiclox (Sodium Fusidate)

Sodium fusidate, the active ingredient in Nadiclox, is a fusidic acid antibiotic presented as a topical formulation for skin application. It is used to treat bacterial skin infections such as impetigo, secondary bacterial skin infections, and infected eczema, primarily in children and adults.

GNH USA supplies Nadiclox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable sourcing for qualified healthcare providers. Our global logistics network ensures timely delivery across multiple regions.

Nadiclox, a fusidic acid antibiotic, is indicated for bacterial skin conditions where it reduces bacterial proliferation. - Impetigo: reduces Staphylococcus aureus and Streptococcus pyogenes colonisation, promoting lesion healing. - Secondary bacterial skin infections: controls infection of compromised skin, limiting spread and inflammation. - Infected eczema: treats bacterial superinfection of eczematous lesions, improving skin integrity.

Topical application of Nadiclox may be associated with local skin reactions and, rarely, systemic hypersensitivity.

Common Side Effects: - Burning sensation: mild transient heat at the application site. - Itching: pruritus localized to treated area. - Redness: erythema around the site of use. - Dryness: skin becomes flaky or rough. - Contact dermatitis: mild allergic skin inflammation.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, hives, or anaphylaxis. - Stevens‑Johnson syndrome: blistering and detachment of skin. - Toxic epidermal necrolysis: extensive skin loss requiring medical care. - Systemic toxicity: rare systemic effects if large areas are applied. - Persistent ulceration: non‑healing skin lesions.

When using Nadiclox, clinicians should observe several precautions to minimise adverse events and ensure optimal efficacy. - Avoid extensive application: limit use to affected areas not exceeding 10% of body surface. - Do not apply to eyes, mucous membranes or broken skin not related to infection. - Discontinue if allergic reaction occurs: stop treatment and seek medical advice. - Use with caution in patients with known hypersensitivity to fusidic acid or related compounds. - Monitor for secondary infection: assess for worsening or new infection signs. - Store at room temperature: keep in original container, protect from moisture and light.

Nadiclox may interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Concurrent systemic antibiotics with overlapping spectrum: may promote resistance. - Use with other topical fusidic acid products: increases risk of local toxicity.

Moderate Interactions (Monitor Closely): - Co‑application with corticosteroid creams: may enhance skin atrophy and reduce antibacterial effect. - Use under occlusive dressings: can increase drug absorption and local irritation. - Combination with antiseptic agents containing alcohol: may cause increased skin dryness.